Description: Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.
Home Page: www.immutep.com
IMM Technical Analysis
Australia Square
Sydney,
NSW
2000
Australia
Phone:
61 2 8315 7003
Officers
| Name | Title |
|---|---|
| Mr. Marc Voigt | CEO, MD, CFO, Chief Bus. Officer & Exec. Director |
| Ms. Deanne Miller LLB | COO, Gen. Counsel & Joint Company Sec. |
| Dr. Frederic Triebel M.D., Ph.D. | Chief Scientific Officer, Chief Medical Officer & Exec. Director |
| Ms. Indira Naidu | Joint Company Sec. |
| Mr. Christian Mueller | Director of Clinical Devel. & Regulatory Affairs |
| Mr. Shengfei Fang | Fin. Director & Assistant Company Sec. |
Exchange: AU
Country: AU : Australia
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.2238 |
| Price-to-Sales TTM: | 56.8735 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |